Trials / Completed
CompletedNCT00195533
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 801 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | piperacillin-tazobactam | |
| DRUG | glycopeptide |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2005-09-19
- Last updated
- 2009-11-16
Locations
12 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00195533. Inclusion in this directory is not an endorsement.